Abstract
Previous research has identified risk factors that may affect the risk of bleeding when individuals are exposed to oral anticoagulants (OAC). It is unclear if this risk continues to exist with newer OACs and more intense monitoring of warfarin therapy. The purpose of this study was to assess the risk of bleeding events in patients on OAC medications including warfarin, apixaban, rivaroxaban, dabigatran or edoxaban based on known risk factors including demographics, medical conditions and concomitant medications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
